Coherus Oncology, Inc. (CHRS)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Developing and Commercializing Biosimilar Products	42.17M	26.39M	257.24M	211.04M	326.55M
Developing and Commercializing Biosimilar Products Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Total	42.17M	26.39M	257.24M	211.04M	326.55M
Total Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States of America	42.17M	26.39M	257.24M	211.04M	326.55M
United States of America Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Total	42.17M	26.39M	257.24M	211.04M	326.55M
Total Growth	59.81%	-89.74%	21.89%	-35.37%	-31.37%

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 29, 2026

Data Sources Report a data error